Day: March 30, 2021

– Recommended Phase 2 Dose for IGM-2323 Expected in 2021 – – Initial Data from Phase 1 Trial of IGM-8444 in Solid Cancers Expected in 2021 – – IND Filing for IGM-7354 Planned in 2021 – – Company to Host Conference Call Today at 4:30 p.m. ET – MOUNTAIN VIEW, Calif., March 30, 2021 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent developments. “IGM reached a number of important milestones in 2020, including the presentation of encouraging initial results from our Phase 1 trial of IGM-2323 at the 2020 ASH Annual Meeting and the initiation of our Phase 1 clinical trial evaluating IGM-8444 in patients...

JASPER, Ind., March 30, 2021 (GLOBE NEWSWIRE) — Kimball International, Inc. (NASDAQ: KBAL) today announced the Company has appointed Valerie R. Love as an independent member of its Board of Directors, effective April 1, 2021. Ms. Love will also serve on the Compensation and Governance Committee and stand for election at the Company’s 2021 annual meeting of shareholders. Ms. Love joined The Coca-Cola Company in August 2019, and currently serves as Chief of Human Resources for the company’s North America operating unit. In this role, Ms. Love’s primary responsibilities are to lead organizational design and people-related strategies within the company in support of acquiring, developing, and retaining the best talent while creating a work environment and culture that enables all associates to function at their best. Prior to joining...

PHOENIX, March 30, 2021 (GLOBE NEWSWIRE) — Mobivity Holdings Corp. (OTCQB:MFON), maker of the award-winning Recurrency platform that increases customer engagement through mobile messaging and personalized digital offers, and drives digital transformation for restaurants, retail and personal care brands, today announced financial results for the fourth quarter (“Q4”) and full-year ending December 31, 2020. Full-Year 2020 Financial HighlightsRevenues increased 32% to $13.3 million compared to $10.1 million in 2019. Gross margin increased to 64% in 2020 compared to 41% in 2019. Net loss was $2.9 million, an improvement of $5.9 million compared to a net loss of $8.8 million in 2019. Cash used in operations for 2020 was $1.4 million compared to $5.7 million during 2019. Stockholder equity improved to $1.7 million in 2020 compared to...

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) — Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of serious degenerative disorders caused by inherited nucleotide repeat expansions, today announced the closing of its previously announced initial public offering of 13,800,000 shares of its common stock, which includes 1,800,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $20.00 per share. Including the option exercise, the aggregate gross proceeds to Design from the offering were approximately $276.0 million, before deducting the underwriting discounts and commissions and offering expenses. The shares began trading...

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today announced that it intends to offer and sell its ordinary shares in an underwritten public offering. All of the shares are being offered by ProQR. In addition, ProQR expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the offering amount in ordinary shares at the public offering price, less underwriting discounts and commissions. The proposed offering is subject to market conditions and other closing conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual terms of the offering. ProQR intends...

30 March 2021, Limassol, Cyprus Reference is made to the announcement on 2 November 2020 regarding a contract award for a 2D survey in the Asia Pacific region. The survey which was originally expected to commence in Q1 2021 has been postponed and is now expected to start in late Q2 2021.     For further queries contact: Gunnar JansenCEOMob: +47 941 19 191 or Erik von KroghCFOMob: +47 930 38 075 All statements in this press release other than statements of historical fact are forward-looking statements and are subject to a number of risks, uncertainties and assumptions that are difficult to predict, and are based upon assumptions as to future events that may not prove accurate. These factors include SeaBird`s reliance on a cyclical industry and the utilization of the company’s vessels. Actual results may differ substantially from...

Press Release AVAILABILITY OF THE INDEPENDENT EXPERT’S REPORT RELATING TO THE FINANCIAL RESTRUCTURING OF VALLOUREC Boulogne-Billancourt (France), March 30, 2021 – Shareholders are informed of the availability of the report dated March 30, 2021 prepared by Finexsi, which was appointed as an independent expert in accordance with Article 261-3 of the Autorité des marchés financiers General Regulations, to assess the fairness for the Company’s shareholders of the financial restructuring of the Company. The independent expert’s report is available in full to the shareholders on the Company’s website (www.vallourec.com) and at the Company’s registered office, in advance of the combined the combined (ordinary and extraordinary) shareholders’ meeting to be held behind closed doors at the Company’s registered office on Tuesday,...

Communiqué de presse MISE A DISPOSITION DU RAPPORT DE L’EXPERT INDEPENDANT ETABLI DANS LE CADRE DE LA RESTRUCTURATION FINANCIERE DE VALLOUREC Boulogne-Billancourt, le 30 mars 2021 – Les actionnaires sont informés de la mise à leur disposition du rapport établi en date du 30 mars 2021 par le cabinet Finexsi, qui est intervenu en qualité d’expert indépendant avec pour mission de rendre un avis, conformément à l’article 261-3 du Règlement général de l’Autorité des marchés financiers, sur le caractère équitable du projet de restructuration financière de la Société pour les actionnaires de la Société. Le rapport de l’expert indépendant est mis à la disposition des actionnaires, en intégralité, sur le site Internet de la Société (www.vallourec.com) et au siège social de la Société, en amont de l’assemblée générale mixte de Vallourec convoquée...